지금 아니면 평생 모험 한 번 할 수 없을 것 같아 너무 넓고도 깊은 IT로 모험갑니다.
set sails! 기다려라, IT!
| Sherlock Holmes | Gregory House, MD |
|---|---|
| Can deduce a great deal from just looking at a person. 인물 관찰로 뛰어난 추리를 해낸다 |
Can deduce and diagnose a great deal just from looking at a person. 인물 관찰로 뛰어난 추리/진단을 해낸다 |
| Holmes' creator based the character on a doctor. 홈즈는 의사 캐릭터를 바탕으로 했다 |
Greg House is a doctor 그렉 하우스는 의사다 |
| His name sounds like "Homes" "홈즈(Homes)"와 발음이 같다 |
His name is another word for "Home" "홈(Home)"의 다른 이름=하우스다 |
| Sherlock Holmes fought deadly criminals 셜록 홈즈는 치명적인 범죄와 싸운다 |
Fights deadly germs, diseases and other medical problems. 하우스는 치명적인 병균,질병들, 의학적 문제들과 싸운다 |
| Used cocaine to escape boredom 지루함에서 탈피하고자 코카인을 한다 -_-;; |
Uses Vicodin for pain in his leg, and also for boredom and the pain of dealing with "stupid" people. '멍청한' 사람들과 부딪힘, 지루함, 그리고 다리 통증을 피하고자 바이코딘을 먹는다 |
| Holmes calls even his best friend by his last name 홈즈의 베프조차 그의 성을 부른다 |
House calls all his associates by their last names 하우스의 모든 동료들은 그의 성을 부른다 |
| Arrogant. Said humility would be a lie 거만하다. '겸손은 거짓이다'고 말한다. |
Greg House is extremely arrogant. 그렉 하우스는 극히 거만하다 |
| Read the agony columns in the paper 신문의 개인상담란을 읽는다 |
Watches soaps, plays video games, etc. 드라마를 보고 비디오 게임을 한다 |
| Languid and lazy when not on a case. 케이스가 없을 때(놀 때)는 기운 없고 게으르다 |
Lazy until he is forced to look into something that intrigues him. 몬가 흥미거리를 찾기 전까지 게으르다 |
| His closest friend had problems with a wound in his leg (although initially, the wound was in his shoulder) 베프는 다리에 문제가 있다 (사실 처음에는 어깨가 아팠다) |
Has a medical problem in his leg. 다리에 의학적 문제가 있다/ 다리가 아프다 -ㅠ- |
| Music is very important to Holmes and he plays the violin. 홈즈에게 음악은 매우 중요하며, 바이올린을 연주한다 |
Music is very important to House and he plays the piano. 하우스에게 음악은 매우 중요하며 피아노를 연주한다 (흠, 일렉 기타 연주하는 것도 보긴 했다) |
| Aloof, although less so with his only friend and roommate. 베프와 룸메에게는 덜 그런 편이지만 대부분에게 쌀쌀맞다 |
Keeps everyone except Wilson at a distance. 윌슨을 뺀 모든 사람들과 거리를 둔다 |
| Sherlock Holmes lives at 221B Baker St. 셜록 홈즈는 베이커 가 221B에 산다 |
In #207 "Hunting" we discover House lives at 221B — we see the number as House and Wilson leave in the morning (but we don't know the street). See a screen caption of the address clearly visible behind Wilson as he leaves House's home. 하우스는 221에 산다- 아직 어느 거리에 사는 지는 알 수 없지만 |
| |||
화이자의 와이어스 인수는 [헬스케어 역사의 2막장] 시작을 아주 큰 징으로다가 치며 알리는, 대격변이라고 봐야겠습니다. GONG~ GONG~
Healthcare, CHAPTER II
이번 화이자 & 와이어스 인수를 통해 안착한 [헬스케어 2막장]은"
◆ Chemical-base의 약물(treatment)에서 Bio-base로의 진입(prevention) 완료
◆ 거대 합체 제약 기업 vs. 거대 합체 제네릭 기업간 일대일 맞짱의 초시
로 간단히 요약될 수 있을 듯 한데요.
어떤 모습으로 다가올지 둑은둑은 합니다! :)
# # #
Pfizer Broadens Beyond Pills with $68 Billion Wyeth Buy
Posted by Sarah Rubenstein
Pfizer has agreed to acquire Wyeth in a $68 billion deal that’s the largest merger in the pharmaceutical industry in nearly a decade. In announcing the deal, the companies made clear that Pfizer has in mind to cut its reliance on traditional pills.
“With its broad and diversified global product portfolio and reduced dependence on small molecules, the new company will be positioned for improved, consistent and stable top-line and [earnings] growth and sustainable shareholder value in the short and long term,” the companies say. “It is expected that no drug will account for more than 10 percent of the combined company’s revenue in 2012.”
That’s putting the best face on the loss of patent protection for cholesterol-fighter Lipitor in late 2011, we suppose. Last year Pfizer registered $12.7 billion in Lipitor sales, or a quarter of company revenue.
Wyeth brings with it big-selling biotechnology products like rheumatoid arthritis remedy Enbrel, which it co-markets with Amgen, and the childhood vaccine Prevnar. Thrown into the mix are an animal health business and a consumer health unit that sells such brands as Advil and ChapStick.
But will that be enough to make up for the Lipitor cliff? A big reason no drug will account for 10% of the combined company’s revenue in 2012 is, of course, because sales of Lipitor will plunge starting in 2011 once generics are available.
As Sanford Bernstein analyst Tim Anderson writes this morning, “While a WYE acquisition would help sooth the painful period that lay ahead of the company, it will only be a partial salve.” The model he put together has the combined company’s revenue falling to $62 billion in 2015 from $73 billion in 2010. Earnings would be flat over those years with aggressive cost cutting, he said.
“Growing a revenue base that big would seem to be nearly impossible,” Anderson wrote.
Update: For the companies’ take on the deal, see the special Web site they created to explain it: www.premierbiopharma.com
[Others]